Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name LINC00152
   Synonyms CYTOR, C2orf59, LINC00152, NCRNA00152, MGC4677
   Region GRCh38_2:87454781-87636740    Sequence
   Ensembl ENSG00000222041
   RefSeq NR_024204
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name triple negative breast cancer
   ICD-0-3 C50  
   Methods qPCR, Western blot
   Sample lung cancer tissues, cell lines (MDA-MB-231, MDA-MB-469, MDAMB-361, MCF-7, T47D, MDA-MB-435, BT474, BT20, and BT483,184A1 and MCF-10A)
   Expression Pattern up-regulated
   Function Description

linc00152 was highly expressed in all basal-like cell lines and in the majority of TNBC tissues. Linc00152 suppression by shRNA significantly inhibited invasion and colony growth. Such suppression also triggered apoptosis in vitro and inhibited tumor growth in vivo.linc00152 partially enhanced breast cancer tumorigenesis by inactivation of the BRCA1/PTEN through DNA methyltransferases.linc00152 as a promising biomarker and therapeutic target for human TNBC treatment.

   Pubmed ID 29156515
   Year 2017
   Title Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer.
   External Links
   Links for  LINC00152 GenBank       HGNC       lncrnadb       Noncode
   Links for  triple negative breast cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.